Aurora Cannabis Inc. (ACB) AI Stock Analysis

Aurora Cannabis Inc., based in Edmonton, Canada, produces, distributes, and sells cannabis and cannabis-derived products for medical and consumer markets. Its offerings encompass dried cannabis, cannabis oils, capsules, edibles, and extracts. The company operates internationally with medical wholesale distribution across the European Union, Australia, the Caribbean, South America, and Israel, as well as hemp-derived CBD sales in the United States. Aurora's adult-use consumer brands include Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, alongside CBD brands Reliva and KG7. Its medical portfolio features brands such as MedReleaf, CanniMed, Aurora, and WMMC.

Between FY2021 and FY2026, revenue generated a 5-year CAGR of 5.5%. Annual revenue peaked in FY2025 at $343.3M with net income of $1.6M and a gross margin of 54.6%, but declined 6.6% in FY2026 to $320.6M with a net loss of -$121.8M. Operating margin in FY2026 reverted to -14.6% after reaching 1.4% in FY2025. For the trailing twelve months ending June 30, 2026, revenue stood at $314.1M with a net profit margin of -38.2%. In the latest quarter ended June 30, 2026, quarterly revenue decreased 8.8% year-over-year, while quarterly earnings dropped 94.7%.

As of June 30, 2026, Aurora Cannabis held $149.2M in cash and short-term investments against total debt of $22.7M, yielding net cash of $126.5M. The company's current ratio was 5.36 and debt-to-equity stood at 0.04. Free cash flow was negative in FY2026 at -$36.1M, reflecting operating cash flow of -$13.5M and capital expenditures of $22.5M. Over the trailing five years, the company's share count expanded by 211.2%.

Aurora Cannabis trades at a price-to-sales multiple of 0.8x and an EV/EBITDA of 15.3x, compared to the median of its US-listed Healthcare peers of 4.1x sales and 12.0x EV/EBITDA. Its forward P/E is 109.9x compared to the peer median of 17.3x. The stock has dropped 24.6% over the past year and 94.3% over five years, underperforming the S&P 500 (SPY), which gained 16.8% over the past year and 83.0% over five years. The stock closed at $3.99 on October 16, 2026, trading 12.3% above its 200-day average.

Wall Street coverage includes 2 Strong Buy and 3 Hold ratings. The mean price target is $6.23, which is 56.1% above the last close of $3.99. For the fiscal year ending March 31, 2027, consensus estimates project revenue of $295.0M and EPS of -$0.17. For the following fiscal year, 4 analysts project revenue of $320.6M and EPS of $0.11. Aurora beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Aurora Cannabis Inc. (ACB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACB income statement, ACB balance sheet, ACB key metrics, ACB analyst forecast, ACB chart. See the ACB stock overview for the latest quote and news.